Earnings Call Summary | NRX Pharmaceuticals(NRXP.US) Q1 2024 Earnings Conference
Earnings Call Summary | NRX Pharmaceuticals(NRXP.US) Q1 2024 Earnings Conference
The following is a summary of the NRx Pharmaceuticals, Inc. (NRXP) Q1 2024 Earnings Call Transcript:
以下是NRx制药公司(NRXP)2024年第一季度财报电话会议记录摘要:
Financial Performance:
财务业绩:
NRx Pharmaceuticals reported a Q1 2024 net loss of $6.5 million, a reduction of 41% year over year.
Research and development expenses dropped from $3.7 million in Q1 2023 to $1.7 million in Q1 2024.
General and administrative expenses decreased by 26% from $5.8 million in Q1 2023 to $4.3 million in Q1 2024.
The company's working capital improved by $8 million due to equity sales and an Alvogen milestone advance, and corporate debts were reduced by $2.2 million.
nRx Pharmicals报告称,2024年第一季度净亏损650万美元,同比下降41%。
研发费用从2023年第一季度的370万美元下降到2024年第一季度的170万美元。
一般和管理费用从2023年第一季度的580万美元下降到2024年第一季度的430万美元,下降了26%。
由于股权出售和Alvogen的里程碑式进展,该公司的营运资金增加了800万美元,公司债务减少了220万美元。
Business Progress:
业务进展:
NRx Pharmaceuticals plans to file two new drug applications for NRX-101, used in the treatment of suicidal bipolar depression, chronic pain, and also shows antibacterial effects against dangerous urinary pathogens.
The Company aims to make a transition from a purely research and development focus to a revenue-generating company by 2024 and is exploring potential treatments for schizophrenia.
NRx is also developing 'HTX-100', an IV ketamine treatment for suicidal depression and exploring partnership opportunities to expand its market presence.
Further business progress includes plans to separate from their current lender to reduce debt costs and improve shareholder benefits.
nRx Pharmicals计划申请两种 NRX-101 新药,用于治疗自杀性双相抑郁症、慢性疼痛,还显示出对危险尿路病原体的抗菌作用。
该公司的目标是到2024年从纯粹的研发重点过渡到创收公司,并正在探索精神分裂症的潜在治疗方法。
nRx 还在开发 “HTX-100”,一种治疗自杀抑郁症的静脉****疗法,并探索合作机会以扩大其市场占有率。
进一步的业务进展包括计划与目前的贷款机构分离,以降低债务成本和改善股东利益。
More details: NRX Pharmaceuticals IR
更多详情: NRX 制药 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。
译文内容由第三方软件翻译。